SCHEMBL7469360

SCHEMBL7469360

COc1ccc(COc2ccc(C(=O)O)cc2OCc2ccc(OC)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.71
RAB9A P51151 4/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
NPC1 O15118 3/20 0.70
POLB P06746 2/20 0.70
RXRA P19793 1/20 0.62
PLA2G4B P0C869 1/20 0.62
TP53 P04637 2/20 0.59
PKM P14618 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
TSHR P16473 1/20 0.57
PAX8 Q06710 1/20 0.56
KLF5 Q13887 1/20 0.56
HIF1A Q16665 1/20 0.56
PTGER1 P34995 2/20 0.56
HPGD P15428 1/20 0.56
PPARA Q07869 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29556803 1.00 MRGPRX4 (0.71) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL9360159 0.96 MRGPRX4 (0.78) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL28336349 0.96 MRGPRX4 (0.69) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL22160247 0.90 RAB9A (0.68) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL23692893 0.89 RAB9A (0.67) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL15680329 0.89 PTPRC (0.59) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL12968385 0.89 RAB9A (0.67) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL8983023 0.88 SMN1; SMN2 (0.57) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL30882515 0.87 RAB9A (0.65) MRGPRX4RAB9ASMN1; SMN2NPC1POLB
SCHEMBL9356585 0.87 MRGPRX4 (0.58) MRGPRX4RAB9ASMN1; SMN2NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4028404-A2 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS Tennor Therapeutics Limited (CN) 2022-07-20 EP disclosed
US-11040987-B2 Penam derivatives for treating bacterial infections TENNOR THERAPEUTICS LIMITED (CN) 2021-06-22 US disclosed
WO-2021048613-A2 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS TENNOR THERAPEUTICS LIMITED (CN) 2021-03-18 WO disclosed
US-20210070774-A1 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS TENNOR THERAPEUTICS LIMITED (CN) 2021-03-11 US disclosed
WO-2019070973-A1 CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS GLADIUS PHARMACEUTICALS CORPORATION (CA) 2019-04-11 WO disclosed
US-20190100534-A1 Cephem Compounds with Latent Reactive Groups GLADIUS PHARMACEUTICALS INC (CA) 2019-04-04 US disclosed
EP-2706062-B1 NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF LEGOCHEM BIOSCIENCES INC (KR) 2018-05-09 EP disclosed
US-9630977-B2 Cephalosporin derivatives and pharmaceutical compositions thereof LEGOCHEM BIOSCIENCES, INC. (KR) 2017-04-25 US disclosed
EP-2341053-B1 CEPHALOSPORIN HAVING CATECHOL GROUP SHIONOGI & CO (JP) 2016-01-13 EP disclosed
EP-2706062-A2 NOVEL CEPHALOSPORIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF LegoChem Biosciences, Inc. (KR) 2014-03-12 EP disclosed
EP-2341053-A1 CEPHALOSPORIN HAVING CATECHOL GROUP Shionogi & Co., Ltd. (JP) 2011-07-06 EP disclosed
EP-0416814-B1 Antibacterial cephalosporin derivatives PFIZER (US) 2002-04-24 EP disclosed
US-5504076-A Cephalosporin compounds PFIZER INC. (US) 1996-04-02 US disclosed
EP-0416810-B1 Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates BEECHAM GROUP PLC (GB) 1995-02-08 EP disclosed
EP-0416410-B1 Piperaziniocephalosporins SHIONOGI & CO (JP) 1994-11-30 EP disclosed
US-5275816-A Cephalosporin derivatives BEECHAM GROUP P.L.C. (GB) 1994-01-04 US disclosed
US-5143910-A PIPERAZINIOCEPHALOSPORINS SHIONOGI & CO., LTD. (JP) 1992-09-01 US disclosed
EP-0416814-A2 Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates BEECHAM GROUP PLC (GB) 1991-03-13 EP disclosed
EP-0416410-A1 Piperaziniocephalosporins SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1991-03-13 EP disclosed
EP-0416810-A2 Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates Beecham Group p.l.c. (GB) 1991-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070774-A1 PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS BPGM, BLVRB, PREP MRGPRX4 4240/4885RAB9A 1446/4885SMN1; SMN2 3514/4885
US-11040987-B2 Penam derivatives for treating bacterial infections BPGM, BLVRB, PREP MRGPRX4 4240/4885RAB9A 1446/4885SMN1; SMN2 3514/4885
US-20190100534-A1 Cephem Compounds with Latent Reactive Groups PGLS, GNE, COMT MRGPRX4 4828/4885RAB9A 3322/4885SMN1; SMN2 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.